# Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

> **NCT02454634** · PHASE1 · COMPLETED · sponsor: **National Center for Tumor Diseases, Heidelberg** · enrollment: 39 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** IDH1 peptide vaccine

## Key facts

- **NCT ID:** NCT02454634
- **Lead sponsor:** National Center for Tumor Diseases, Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-09-19
- **Final completion:** 2017-09-19
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2018-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454634, "Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02454634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*